| scholarly article | Q13442814 |
| P2093 | author name string | Lei Zhang | |
| Jun-Jie Yang | |||
| Wei-Zheng Li | |||
| Kyle Stirling | |||
| P2860 | cites work | Human gut microbiota transferred to germ-free NOD mice modulate the progression towards type 1 diabetes regardless of the pace of beta cell function loss in the donor | Q91531541 |
| The oral microbiome profile and biomarker in Chinese type 2 diabetes mellitus patients | Q91557504 | ||
| Dietary fibers as emerging nutritional factors against diabetes: focus on the involvement of gut microbiota | Q91955902 | ||
| Oral Microbiome Signatures in Diabetes Mellitus and Periodontal Disease | Q91986013 | ||
| The gut microbiota in type 1 diabetes: friend or foe? | Q92399700 | ||
| Role of gut microbiota in type 2 diabetes pathophysiology | Q92416693 | ||
| Response of gut microbiota in type 2 diabetes to hypoglycemic agents | Q92608315 | ||
| The gut flora as a forgotten organ | Q24550824 | ||
| Innate immunity and intestinal microbiota in the development of Type 1 diabetes | Q24647312 | ||
| The Intestinal Microbiota in Metabolic Disease | Q26750612 | ||
| Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders | Q26752979 | ||
| Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective | Q26863476 | ||
| Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation | Q27022777 | ||
| An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
| Metformin and the gastrointestinal tract | Q28079250 | ||
| The gut microbiota as an environmental factor that regulates fat storage | Q28131676 | ||
| A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance | Q28240815 | ||
| Environmental risk factors for type 1 diabetes | Q28276366 | ||
| Therapeutic potential of fecal microbiota transplantation | Q28298108 | ||
| Can probiotics modulate human disease by impacting intestinal barrier function? | Q28817192 | ||
| Metabolite profiles and the risk of developing diabetes | Q29615359 | ||
| Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome | Q29616853 | ||
| Personalized Nutrition by Prediction of Glycemic Responses. | Q33445995 | ||
| The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities | Q33653853 | ||
| Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study | Q33810793 | ||
| Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. | Q33992194 | ||
| Gut microbiome composition is linked to whole grain-induced immunological improvements | Q34434395 | ||
| Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology | Q34481919 | ||
| Human gut microbes impact host serum metabolome and insulin sensitivity | Q34534015 | ||
| An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice | Q34785134 | ||
| How informative is the mouse for human gut microbiota research? | Q34818253 | ||
| Human gut microbiota changes reveal the progression of glucose intolerance | Q34980773 | ||
| Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity | Q35063271 | ||
| Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans | Q35080321 | ||
| Long term effect of gut microbiota transfer on diabetes development | Q35157830 | ||
| The oral microbiome diversity and its relation to human diseases | Q35229608 | ||
| Antibiotics in early life and obesity | Q35501942 | ||
| Insights into the role of the microbiome in obesity and type 2 diabetes | Q35533602 | ||
| The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes | Q35557877 | ||
| Probiotics, prebiotics, synbiotics and insulin sensitivity | Q47645890 | ||
| Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism | Q47685140 | ||
| A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice | Q48052752 | ||
| High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults. | Q48343290 | ||
| Aberrant intestinal microbiota in individuals with prediabetes. | Q49589329 | ||
| Precision nutrition for prevention and management of type 2 diabetes | Q50046253 | ||
| The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. | Q51091374 | ||
| Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. | Q51144292 | ||
| Short-chain fatty acids suppress food intake by activating vagal afferent neurons. | Q52558531 | ||
| Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. | Q52682856 | ||
| Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. | Q52688725 | ||
| Probiotic Species in the Modulation of Gut Microbiota: An Overview. | Q55027051 | ||
| Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. | Q55241521 | ||
| Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. | Q55360178 | ||
| Temporal development of the gut microbiome in early childhood from the TEDDY study | Q57807193 | ||
| The human gut microbiome in early-onset type 1 diabetes from the TEDDY study | Q57807205 | ||
| Oral LPS Dosing Induces Local Immunological Changes in the Pancreatic Lymph Nodes in Mice | Q63728876 | ||
| Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases | Q63916389 | ||
| Extensive transmission of microbes along the gastrointestinal tract | Q63952158 | ||
| Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study | Q65548730 | ||
| The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease | Q89103977 | ||
| Benefaction of probiotics for human health: A review | Q89432874 | ||
| Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice | Q89714366 | ||
| Microbial balance in the intestinal microbiota and its association with diabetes, obesity and allergic disease | Q90026557 | ||
| Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition | Q90096722 | ||
| Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial | Q91116854 | ||
| Metformin and gut microbiota: their interactions and their impact on diabetes | Q91344018 | ||
| The role of microbial amino acid metabolism in host metabolism | Q35586016 | ||
| The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon | Q35627470 | ||
| Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults | Q35733844 | ||
| Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders | Q35813376 | ||
| Branched-chain amino acids as biomarkers in diabetes | Q35814709 | ||
| Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber | Q35826580 | ||
| Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice | Q35840309 | ||
| Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota | Q35860108 | ||
| The role of the intestinal microbiota in type 1 diabetes mellitus | Q35884681 | ||
| Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. | Q35956912 | ||
| Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans | Q36004640 | ||
| Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance | Q36037520 | ||
| Diet-microbiota interactions as moderators of human metabolism | Q36069065 | ||
| Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes | Q36323689 | ||
| Gut Microbiota in Cardiovascular Health and Disease | Q36329055 | ||
| Metabolic endotoxemia with obesity: Is it real and is it relevant? | Q36414963 | ||
| The role of the gut microbiota in energy metabolism and metabolic disease | Q37481953 | ||
| Influence of diet on the gut microbiome and implications for human health. | Q37742351 | ||
| Gut microbiota and the pathogenesis of insulin resistance | Q37856877 | ||
| Branched-chain amino acids as pharmacological nutrients in chronic liver disease | Q37874555 | ||
| Intestinal microbiota and obesity | Q37976362 | ||
| Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. | Q38062787 | ||
| New Horizons for the Study of Dietary Fiber and Health: A Review | Q38723574 | ||
| Roseburia spp.: a marker of health? | Q38764022 | ||
| Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. | Q38780040 | ||
| Association of oral microbiome with type 2 diabetes risk | Q38972544 | ||
| The intestinal epithelial barrier: a therapeutic target? | Q39009998 | ||
| Gut microbiota: A player in aging and a target for anti-aging intervention | Q39097545 | ||
| Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. | Q39374045 | ||
| TGR5-mediated bile acid sensing controls glucose homeostasis | Q39805262 | ||
| Diabetes Enhances IL-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity. | Q40486007 | ||
| Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept | Q41662018 | ||
| Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. | Q43067512 | ||
| The gut microbiota and obesity: from correlation to causality | Q44559588 | ||
| Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug | Q46362610 | ||
| Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability | Q46697141 | ||
| A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. | Q46858371 | ||
| Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system | Q46859768 | ||
| "Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans". | Q47198092 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 293-308 | |
| P577 | publication date | 2020-07-01 | |
| P1433 | published in | World journal of diabetes | Q27723539 |
| P1476 | title | Gut microbiota and diabetes: From correlation to causality and mechanism | |
| P478 | volume | 11 |
Search more.